From bench to clinic with apoptosis-based therapeutic agents

Nature

Volumn 407, Issue 6805, 2000, Pages 810-816

  Nicholson, D W ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCL 2 ANTISENSE OLIGONUCLEOTIDE; BCL X ANTISENSE OLIGONUCLEOTIDE; CASPASE; CASPASE INHIBITOR; CISPLATIN; CYTARABINE; FLUDARABINE; G 3139; IRINOTECAN; MITOXANTRONE; NEW DRUG; PROTEIN BCL 2; SURVIVIN; TAXOL; TAXOTERE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; CELL DEATH; CELL SURVIVAL; DRUG DESIGN; DRUG RESEARCH; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; APOPTOSIS; CASPASES; ENZYME INHIBITORS; FORECASTING; HUMAN; MEMBRANE GLYCOPROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR NECROSIS FACTOR;

EID: 0034641932     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/35037747     Document Type: Review

References (63)

1. Mechanisms and functions of cell death
2. Structure-based discovery of an organic compound that binds bcl-2 protein and induces apoptosis of tumor cells
3. The Bcl-2 protein familly: Arbiters of cell survival
4. Bcl-2 family proteins
5. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair
6. Regulation of lymphocyte survival by the bcl-2 gene family
7. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice
8. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
9. Bcl-2 antisense plus dacarbazine therapy for malignant melanoma
10. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
11. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells
12. Splicing and dicing apoptosis genes
13. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides
14. Cholangiocarcinomas express Fas ligand and disable the Fas receptor
15. Death receptors: Signaling and modulation
16. Apoptosis induced by death receptors
17. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death
18. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
19. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
20. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
21. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
22. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
23. Cell death attenuation by 'Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex
24. Safety and antitumor activity of recombinant soluble Apo2 ligand
25. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
26. Control of apoptosis signaling by Apo2 ligand
27. TRAIL: A molecule with multiple receptors and control mechanisms
28. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells
29. Molecular determinants of response to TRAIL in killing of normal and cancer cells
30. p53 mutations in human cancers
31. Wild-type p53 transactivates the KILLER/DRS gene through an intronic sequence-specific DNA-binding site
32. The Apo2L/TRAIL system: Therapeutic opportunities
33. Steering anti-cancer drugs away from the TRAIL
34. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
35. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL
36. Triggering cell death: The crystal structure of Apo2L/TRAIL in a complex with death receptor 5
37. Human ICE/CED-3 protease nomenclature
38. A novel heterodimeric cysteine protease is required for interleukin-1β processing monocytes
39. Molecular cloning of the interleukin-1β converting enzyme
40. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme
41. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
42. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice
43. Caspase structure, proteolytic substrates, and function during apoptotic cell death
44. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis
45. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis
46. Inhibition of human caspases by peptide-based and macromolecular inhibitors
47. A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis
48. Caspase inhibition and limitation of myocardial infarct size: Protection against lethal reperfusion injury
49. A specific inhibitor of apoptosis decreases tissue injury after intestinal ischemia-reperfusion in mice
50. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation
51. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family
52. Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury
53. Intracerebral injection of caspase-3 inhibitor prevents neuronal apoptosis after kalnic acid-evoked status epilepticus
54. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model
55. Caspase inhibition reduces apoptosis and increases survival of nigral transplants
56. Neuroprotection by a caspase inhibitor in acute bacterial meningitis
57. Peptidomimetic fluoromethylketone rescues mice from lethal endoroxic shock
58. Prevention of lymphocyte cell death in sepsis improves survival in mice
59. Caspase-8 is required for cell death induced by expanded polyglutamine repeats
60. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract
61. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation
62. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein
63. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality